2-fluoroethanol | 40017-45-6

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氟化物
• 英文名称: 2-fluoroethanol
• 英文别名: monofluoroethanol；fluoroethanol；fluoroethyl alcohol；1-Fluoroethanol
• CAS: 40017-45-6
• 化学式: C₂H₅FO
• 分子量: 64.0595
• InChiKey: OGBOTYGRYZDLMG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  4
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(3-(2,3-Dihydrobenzo[b][1,4]dioxin-6-ylamino)-5-fluoroimidazo[1,2-a]pyridin-2-yl)-3,5-difluorophenol 、 2-fluoroethanol 、 四氢呋喃 在 title compound 、 甲醇 作用下， 生成 4-(3-(2,3-Dihydrobenzo[b][1,4]dioxin-6-ylamino)-5-(2-fluoroethoxy)imidazo[1,2-a]pyridin-2-yl)-3,5-difluorophenol
  参考文献：
  名称：

  IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS

  摘要：

  本文公开了I式化合物，或其药学上可接受的盐、酯、酰胺等；以及调节大麻素CB2受体活性的方法，包括将I式化合物与大麻素CB2受体接触。还公开了通过正电子发射断层扫描成像组织的方法，该方法包括向受试者注射I式化合物，其中该化合物包含放射性同位素。还公开了通过使用含有放射性同位素的I式化合物来测量受试者组织中大麻素CB2受体的相对浓度的方法。此外，还公开了一种诊断受试者疾病的方法。

  公开号：

  US20110206607A1

文献信息

• Arylethenesulfonamide derivatives and drug composition containing the
  申请人：Yamanouchi Pharmaceutical Co., Ltd.

  公开号：US06083955A1

  公开（公告）日：2000-07-04

  Novel arylethenesulfonamide derivative having a high affinity for drugs, especially endoserine receptors, and represented by general formula (I); pharmaceutically acceptable salts thereof; and drugs comprising the same as the active ingredient, especially endoserine receptor antagonist, wherein Ar: optionally substituted aryl group or optionally substituted five- to six-membered heteroaryl group; X: oxygen atom, sulfur atom or a group represented by a formula --NH--; Y: oxygen atom or sulfur atom; R.sub.1 : hydrogen atom, optionally halogen-substituted lower alkyl group, cycloalkyl group, optionally substituted aryl group or optionally substituted five- to six-membered heteroaryl group. R.sub.2 : lower alkyl group, lower alkenyl group or lower alkynyl group where each of which may be substituted with one to three substituent(s) selected from a group consisting of hydroxyl group, lower alkoxy group, cycloalkyl group, halogen atom, carboxyl group and lower alkoxycarbonyl group; R.sub.3 : phenyl group which may be substituted with one to four substituent(s) selected from a group consisting of optionally halogen-substituted lower alkyl group, lower alkoxy group, halogen atom, lower alkylthio group, lower alkylsulfinyl group, lower alkanesulfonyl group, carboxyl group, lower alkoxycarbonyl group and carbamoyl group; and R.sub.4 and R.sub.5 : they may be same or different and each is hydrogen atom or lower alkyl.

  具有对药物，尤其是内源性丝氨酸受体高亲和力的新型芳基乙烯磺酰胺衍生物，其通式表示为（I）; 其药学上可接受的盐; 以及作为活性成分的药物，尤其是内源性丝氨酸受体拮抗剂，其中Ar：可选取代芳基或可选取代的五至六元杂环芳基; X：氧原子，硫原子或由公式--NH--表示的基团; Y：氧原子或硫原子; R.sub.1：氢原子，可选取代的卤代低烷基，环烷基，可选取代的芳基或可选取代的五至六元杂环芳基。R.sub.2：低烷基，低烯基或低炔基，其中每个基团可能被选自羟基，低烷氧基，环烷基，卤原子，羧基和低烷氧羰基基团的一个到三个取代基所取代; R.sub.3：苯基，其可能被选自一个到四个取代基所取代，所选取代基包括可选取代的卤代低烷基，低烷氧基，卤原子，低烷硫基，低烷基硫醇基，低烷基磺酰基，羧基，低烷氧羰基基团和氨基甲酰基; R.sub.4和R.sub.5：它们可能相同或不同，每个都是氢原子或低烷基。
• QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND VARIOUS THERAPEUTIC USES THEREOF.
  申请人：CLAUSS Annie

  公开号：US20120115846A1

  公开（公告）日：2012-05-10

  The subject matter of the invention is quinazolinedione derivatives of formula (I), methods for obtaining same and therapeutic uses thereof, such as cancer, diabetes, muscle diseases, bone diseases, cardiovascular diseases, central nervous system diseases, peripheral nervous system diseases, inter alia.

  本发明的主题是公式（I）的喹唑啉二酮衍生物，其获得方法和治疗用途，例如癌症、糖尿病、肌肉疾病、骨骼疾病、心血管疾病、中枢神经系统疾病、外周神经系统疾病等。
• Quinazolinedione derivatives, preparation thereof and various therapeutic uses thereof
  申请人：Clauss Annie

  公开号：US08722659B2

  公开（公告）日：2014-05-13

  The subject matter of the invention is quinazolinedione derivatives of formula (I), methods for obtaining same and therapeutic uses thereof, such as cancer, diabetes, muscle diseases, bone diseases, cardiovascular diseases, central nervous system diseases, peripheral nervous system diseases, inter alia.

  本发明的主题是公式（I）的喹唑啉二酮衍生物，以及获得其的方法和治疗用途，例如癌症、糖尿病、肌肉疾病、骨疾病、心血管疾病、中枢神经系统疾病、外周神经系统疾病等。
• Discovery and optimization of 5-fluoro-4,6-dialkoxypyrimidine GPR119 agonists
  作者：Daniel J. Buzard、Sun Hee Kim、Juerg Lehmann、Sangdon Han、Imelda Calderon、Amy Wong、Andrew Kawasaki、Sanju Narayanan、Rohit Bhat、Tawfik Gharbaoui、Luis Lopez、Dawei Yue、Kevin Whelan、Hussien Al-Shamma、David J. Unett、Hsin-Hui Shu、Shiu-Feng Tung、Steve Chang、Ching-Fen Chuang、Michael Morgan、Abu Sadeque、Zhi-Liang Chu、James N. Leonard、Robert M. Jones

  DOI：10.1016/j.bmcl.2014.06.071

  日期：2014.9

  A series of 5-fluoro-4,6-dialkoxypyrimidine GPR119 modulators were discovered and optimized for in vitro agonist activity. A lead molecule was identified that has improved agonist efficacy relative to our clinical compound (APD597) and possesses reduced CYP2C9 inhibitory potential. This optimized lead was found to be efficacious in rodent models of glucose control both alone and in combination with a Dipeptidyl peptidase-4 (DPP-4) inhibitor.
• IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS
  申请人：Olsson Roger

  公开号：US20110206607A1

  公开（公告）日：2011-08-25

  Disclosed herein are compounds of Formula (I), or a pharmaceutically acceptable salt, ester, amide, thereof; and methods of modulating the activity of a cannabinoid CB2 receptor comprising contacting a compound of Formula I with the cannabinoid CB2 receptor. Also disclosed are methods of imaging of a tissue by positron emission tomography, the method comprising administering to the subject a compound of Formula I, wherein the compound comprises a radioisotope. Also disclosed are methods of measuring the relative concentration of cannabinoid CB2 receptors in tissue of a subject, by using a compound of Formula I which comprises a radioisotope. In addition, method of diagnosing a disorder in a subject are disclosed.

  本文公开了I式化合物，或其药学上可接受的盐、酯、酰胺等；以及调节大麻素CB2受体活性的方法，包括将I式化合物与大麻素CB2受体接触。还公开了通过正电子发射断层扫描成像组织的方法，该方法包括向受试者注射I式化合物，其中该化合物包含放射性同位素。还公开了通过使用含有放射性同位素的I式化合物来测量受试者组织中大麻素CB2受体的相对浓度的方法。此外，还公开了一种诊断受试者疾病的方法。